JPS5791921A - Medicine and manufacture - Google Patents

Medicine and manufacture

Info

Publication number
JPS5791921A
JPS5791921A JP56153513A JP15351381A JPS5791921A JP S5791921 A JPS5791921 A JP S5791921A JP 56153513 A JP56153513 A JP 56153513A JP 15351381 A JP15351381 A JP 15351381A JP S5791921 A JPS5791921 A JP S5791921A
Authority
JP
Japan
Prior art keywords
medicine
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP56153513A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0155244B2 (enExample
Inventor
Uiriamu Baansutetsudo Barii
Jiyon Ruuku Debitsudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10516342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS5791921(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Publication of JPS5791921A publication Critical patent/JPS5791921A/ja
Publication of JPH0155244B2 publication Critical patent/JPH0155244B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP56153513A 1980-09-27 1981-09-28 Medicine and manufacture Granted JPS5791921A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8031298 1980-09-27

Publications (2)

Publication Number Publication Date
JPS5791921A true JPS5791921A (en) 1982-06-08
JPH0155244B2 JPH0155244B2 (enExample) 1989-11-22

Family

ID=10516342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56153513A Granted JPS5791921A (en) 1980-09-27 1981-09-28 Medicine and manufacture

Country Status (15)

Country Link
US (1) US4537887A (enExample)
EP (1) EP0049061B1 (enExample)
JP (1) JPS5791921A (enExample)
AU (1) AU549321B2 (enExample)
CA (1) CA1187796A (enExample)
DE (1) DE3172028D1 (enExample)
ES (1) ES8307095A1 (enExample)
GB (1) GB2084016B (enExample)
GR (1) GR75049B (enExample)
HK (1) HK17386A (enExample)
IE (1) IE51597B1 (enExample)
MY (1) MY8600353A (enExample)
NZ (1) NZ198241A (enExample)
PT (1) PT73686A (enExample)
ZA (1) ZA816272B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59104319A (ja) * 1982-12-06 1984-06-16 Chugai Pharmaceut Co Ltd 抗菌剤およびそのキツト

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0080862B1 (en) * 1981-12-02 1985-09-25 Beecham Group Plc Pharmaceutical formulation comprising beta-lactam antibiotics
DE3887179T2 (de) * 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
US5211958A (en) * 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
ATE108996T1 (de) * 1988-02-25 1994-08-15 Brocades Pharma Bv Verfahren zur herstellung eines pharmazeutischen granulats.
US5643902A (en) * 1990-04-26 1997-07-01 Pfizer Inc. Veterinary treatment
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
GB9413542D0 (en) * 1994-07-05 1994-08-24 Smithkline Beecham Plc Pharmaceutical formulations
EP0879772B1 (en) * 1994-08-05 2002-06-12 Smithkline Beecham Plc Pharmaceutical substances in containers and method of dessicating them
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
DZ1926A1 (fr) * 1994-09-03 2002-02-17 Smithkline Beckman P L C Formulations pharmaceutiques.
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
DZ2028A1 (fr) * 1995-05-03 2002-10-23 Smithkline Beecham Plc Médicaments destinés au traitement d'infections bactériennes en pédiatrie.
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
NZ337247A (en) * 1995-09-07 2001-05-25 Smithkline Beecham Corp Pharmaceutical tablet formulation comprising 875mg amoxycillin
ITMI952354A1 (it) * 1995-11-16 1997-05-16 Smithkline Beecham Spa Composizione farmaceutica
US5801796A (en) * 1996-05-10 1998-09-01 International Business Machines Corporation Stacked parallax-free liquid crystal display cell
GB9617780D0 (en) * 1996-08-24 1996-10-02 Smithkline Beecham Plc Method of treatment
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
CA2280857A1 (en) * 1997-02-14 1998-08-20 Smithkline Beecham Laboratoires Pharmaceutiques Pharmaceutical formulations comprising amoxocyllin and clavulanate
US6296871B1 (en) * 1998-04-12 2001-10-02 Ranbaxy Laboratories Limited Stable solid pharmaceutical compositions containing enalapril maleate
US6177421B1 (en) 1999-05-04 2001-01-23 Fuisz International Ltd. Amoxicillin and clavulanate composition
IE990159A1 (en) * 1999-02-26 2000-09-20 Fuisz Internat Ltd Storage Stable Amoxycillin and Clavulanate Suspension Composition.
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
BR0013366A (pt) * 1999-08-16 2002-07-23 Revaax Pharmaceuticals Llc Métodos para tratar um distúrbio comportamental, um paciente humano, doença de próstata, distúrbios de ansiedade e cognitivos em um paciente humano afligido com uma condição ou disposto ao desenvolvimento de uma condição distinguida pelo menos em parte pela concentração de glutamato extracelular anormal no cérebro ou em outro tecido nervoso, distúrbio comportamental nas espécies humana, canina, felina e equina e um paciente afligido com ou disposto a desenvolver uma doença compreendendo concentrações de glutamato anormalmente elevadas em tecido neuronal ou nìveis de naaladase elevados em tecido prostático e com esclerose múltipla e para realçar a função cognitiva, formulação farmacêutica e usos de um inibidor da atividade de peptidase de uma dipeptidase ácida ligada em alfa n-acetilada e de um composto de beta-lactama
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
AU2001292185A1 (en) 2000-10-12 2002-04-22 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
KR100456833B1 (ko) * 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
EP1902708A1 (de) 2006-09-25 2008-03-26 Losan Pharma GmbH Wirkstoff enthaltende stabilisierte feste Arzneimittelformen und Verfahren zu ihrer Herstellung
US20100255099A1 (en) * 2007-10-26 2010-10-07 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
MX2010004556A (es) 2007-10-26 2010-07-01 Rexahn Pharmaceuticals Inc Formulacion farmaceutica de acido clavulanico.
JP6441890B2 (ja) 2013-03-15 2018-12-19 ブレインツリー・ラボラトリーズ，インコーポレイテッド 硫酸塩の両用経口薬学的組成物錠剤およびその使用の方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2843318A1 (de) * 1977-10-11 1979-04-12 Beecham Group Ltd Pharmazeutische praeparate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (de) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Verfahren zum Tablettieren von hygroskopischen Praeparaten
US3432593A (en) * 1963-09-18 1969-03-11 Key Pharm Inc Delayed and sustained release type pharmaceutical preparation
GB1209634A (en) * 1967-06-29 1970-10-21 Rit Rech Ind Therapeut Stabilized antibiotic compositions for animal feeding and process for preparing them
DE2512247A1 (de) * 1975-03-20 1976-10-14 Thomae Gmbh Dr K Gegen feuchtigkeit stabilisierte presslinge mit feuchtigkeitsempfindlichen inhaltsstoffen
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
IL58461A0 (en) * 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a clavulanic acid salt
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2843318A1 (de) * 1977-10-11 1979-04-12 Beecham Group Ltd Pharmazeutische praeparate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59104319A (ja) * 1982-12-06 1984-06-16 Chugai Pharmaceut Co Ltd 抗菌剤およびそのキツト

Also Published As

Publication number Publication date
GB2084016B (en) 1985-04-17
GR75049B (enExample) 1984-07-12
AU7568481A (en) 1982-04-08
GB2084016A (en) 1982-04-07
IE812232L (en) 1982-03-27
CA1187796A (en) 1985-05-28
PT73686A (pt) 1981-10-01
MY8600353A (en) 1986-12-31
NZ198241A (en) 1983-12-16
US4537887A (en) 1985-08-27
HK17386A (en) 1986-03-21
DE3172028D1 (en) 1985-10-03
ES505803A0 (es) 1983-06-16
EP0049061A1 (en) 1982-04-07
ES8307095A1 (es) 1983-06-16
JPH0155244B2 (enExample) 1989-11-22
IE51597B1 (en) 1987-01-21
ZA816272B (en) 1982-09-29
EP0049061B1 (en) 1985-08-28
AU549321B2 (en) 1986-01-23

Similar Documents

Publication Publication Date Title
JPS5791921A (en) Medicine and manufacture
JPS5750913A (en) Nifedipin-containing solid medicine and manufacture
JPS5777616A (en) Medicinal composition and manufacture
JPS5723661A (en) Methacrylate-undercoated silicone finish-coated product and manufacture
JPS57118794A (en) Imunosome and preparation thereof
JPS57106535A (en) Peralumina-nepheline/kalcilite glass-ceramic and manufacture thereof
JPS56169690A (en) Xanthinederivative and manufacture
JPS5718624A (en) Drug and manufacture
JPS56130335A (en) Radial-tire and its manufacture
JPS5788172A (en) Pyroxicam and manufacture
JPS56103199A (en) Indoxymaltodextrin and its manufacture
GB2070016B (en) 17-acyloxy-5-corticoids and 17-acyloxy-5-corticoids
JPS56131539A (en) Substituted bromfluorobenzene and manufacture
JPS5711969A (en) 2-nitroimidazoles and manufacture
JPS57123190A (en) Novel esters, manufacture and medicine containing same
JPS57118521A (en) Blood products and manufacture
JPS56164191A (en) Theophyllinylmethyldioxolane derivative, its manufacture and medicine
JPS5756429A (en) Nose medicine and manufacture
JPS57120526A (en) Medicine containing kallikrein and manufacture
JPS56138154A (en) Desacetylthymosin-alpha-1 and manufacture
IL62848A0 (en) Carbapenams and carbapen-2-ems and their preparation
JPS57122092A (en) S-bromo-dithiophosphoric acid-, -dithiophosphoric acid- and -dithiophosphinic acid-derivatives and manufacture thereof
JPS57181052A (en) 2-ketosulfonamide and manufacture
JPS56154476A (en) 4-halogenated-oxetane-2-ones and manufacture
JPS57158745A (en) Novel n-acyl-polypeptides and manufacture